Cerebrolysin

Neurotrophic peptide complex

Cerebrolysin (Neurotrophic peptide complex) is a cognitive & mood research compound. Porcine-derived mix of neuropeptides and amino acids with BDNF/NGF-like neurotrophic and neuroprotective activity.

How Cerebrolysin works

Porcine-derived mix of neuropeptides and amino acids with BDNF/NGF-like neurotrophic and neuroprotective activity.

Proposed benefits

Researched for focus, memory, neuroprotection, mood and stress resilience.

Where to get Cerebrolysin

The evidence for Cerebrolysin

Graded by what exists behind each claim.

✅ Clinically validated

• Substantial randomized human data, and genuinely mixed. Registered in over forty countries, mostly for stroke and dementia. Cochrane reviews of Cerebrolysin in acute ischemic stroke found no convincing evidence of benefit on death or dependence, while several individual trials — many conducted in the countries where it is marketed — report improvement.
• The honest read is that the strongest positive trials tend to be the ones with the most industry proximity, and the independent meta-analyses are the least impressed. That pattern is worth knowing rather than picking a side.

📊 Correlative data

• Long clinical use in Europe, Russia and Asia for traumatic brain injury and cognitive decline. Reported experience in the research community is of a cumulative effect over a course of daily injections rather than anything acute — which matches how it is prescribed clinically.

🧪 Theoretical / extrapolated

• A porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and amino acids. Proposed to act as a neurotrophic factor mimetic, mirroring BDNF and NGF activity.
• Being an extract rather than a defined molecule is the structural weakness in every claim made for it — batch composition varies, and you cannot fully characterize a mechanism when the contents are defined by a process. Same caveat as Actovegin.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Cerebrolysin actually does

Cerebrolysin is derived from porcine brain. That is the whole definition, and it is the definition the Cochrane review uses in its own background sentence Ziganshina 2023. There is no active ingredient named on this page because there is none named on the product, in the trials, or in the regulatory literature of any country where it is registered.

But ‘undefined mixture’ is not one category, and the distinction matters more than anybody makes it. This site carries another biological mixture, Actovegin, and the two are made in opposite ways. Actovegin is calf blood, ultrafiltered: a size cut-off applied to a fluid, so everything in the vial already existed in the animal and the process only decided what to keep. Cerebrolysin is pig brain, enzymatically digested: a protease is applied to tissue protein and the fragments in the ampoule did not exist in the pig. They were created by the cut sites the enzyme chose and the point at which the reaction was stopped.

Follow that through, because it changes what a batch is. A filtration product is defined by a pore size, which is a physical constant. A digestion product is defined by a reaction endpoint — enzyme, ratio, temperature, time — and reaction endpoints drift. Two ampoules made three years apart are identical only to the extent that two protein digests are identical, which in every other field of protein chemistry is a thing you have to demonstrate rather than assume. No peptide map of Cerebrolysin has been published. Not a list of the fragments, not their relative abundances, not a lot-comparison. For a product whose identity is its peptide distribution, that is the specification, and it is missing.

The proposed mechanism, and what actually got measured. The claim is neurotrophic mimicry — that small peptides do what BDNF, GDNF and NGF do, since those proteins are far too large to cross into the brain from the blood. The pathways that have actually been named in the porcine-brain-hydrolysate literature are downstream survival signals: PI3K/Akt activation with Bcl-2 upregulation in hippocampal neurons of vascular dementia mice Wu 2021, and Wnt/beta-catenin activation in a myelin-damage model Zhang 2024. Both of those measurements were made on the cousin preparation rather than on Cerebrolysin, which brings this page immediately to the question it exists to answer.

Are Cerebrolysin and cerebroprotein hydrolysate the same thing? Here is the honest answer, and it is the same answer on both pages because it is one question. They are the same class of preparation: porcine brain, enzymatically hydrolyzed, filtered to leave low-molecular-weight peptides and free amino acids. The cousin's own papers define it in words that would serve as a definition of Cerebrolysin — ‘a neuropeptide preparation which consists of several amino acids and small molecular peptides’ Wu 2021, ‘a mixture of hydrolyzed peptides and amino acids’ Zhang 2024. What is not established is that they are the same product: they come from different manufacturers, they are sold in different physical forms and different units, their clinical trial bases never cite each other, and nobody has ever published a compositional comparison of the two. So ‘the same’ and ‘different’ are both currently unproven, which is a more useful thing to know than either claim.

Cell, rodent, human — and where it stops

The preclinical rung has to be stated carefully, and the care is the point. The rodent and cell work that could be resolved for this cohort was done on cerebroprotein hydrolysate, not on Cerebrolysin Wu 2021 Zhang 2024. Whether it transfers is exactly the identity question above. This page will not borrow the cousin's mouse data and print it under this name, which is what most writing about these two products quietly does.

Human, trial set one: traumatic brain injury, and it is positive. A prospective meta-analysis of two phase IIIb/IV randomized trials, 185 patients with Glasgow Coma Scale 6–12, given 50 mL of Cerebrolysin or saline per day for ten days, followed by two further cycles of 10 mL per day for 10 days. The combined Mann-Whitney estimate was 0.60 (95% CI 0.52 to 0.66, p = 0.0156) at day 30 and 0.60 (95% CI 0.52 to 0.68, p = 0.0146) at day 90, which the authors describe as a small-to-medium effect with comparable safety Vester 2021.

Human, trial set two: acute ischemic stroke, and it is not. The Cochrane review pooled 7 randomized trials and 1,773 participants. All-cause death: risk ratio 0.96, 95% CI 0.65 to 1.41, from 6 trials and 1,689 participants, moderate-certainty evidence. Serious adverse events overall: RR 1.16, 95% CI 0.81 to 1.66. Non-fatal serious adverse events: RR 2.39, 95% CI 1.10 to 5.23. The authors' conclusion is that Cerebrolysin probably has no beneficial effect on preventing all-cause death in acute ischemic stroke, with a potential increase in non-fatal serious adverse events Ziganshina 2023.

And now the obstacle, which is arithmetic and which nobody writes. The regimen that produced the positive result is 50 mL a day Vester 2021. Intramuscular injection tolerates roughly 2–5 mL per site in an adult; beyond that the volume has nowhere to go. Fifty milliliters is therefore ten to twenty-five separate intramuscular injections in one day, every day for ten days. Nobody does that, and this site's own card lists the route as IM and the dose as 5–10 mL per course — which is between one hundredth and one fiftieth of the trial's loading exposure. The positive human evidence for this product exists at a dose that cannot be delivered by the route people actually use. That is not a dose disagreement, it is a physical impossibility, and it is the single most important sentence on this page.

Two further obstacles. (1) Population. CAPTAIN enrolled people with Glasgow Coma Scale 6–12 — moderate to severe brain injury, in hospital Vester 2021. Cochrane's trials were acute ischemic stroke Ziganshina 2023. Neither is a healthy adult running a nootropic course. (2) The one pediatric trial in this class gave 14 days intravenously and then 76 days orally Hua 2025, which is a third route again, with its own unmeasured absorption.

Cerebrolysin pharmacokinetics — how much of it actually gets in

The card says a half-life of about 24 hours. There is no source for that number, and there cannot be one, because a half-life is a property of an analyte and this product does not declare one.

What degrades it. Split the vial in two. The peptide fraction is what plasma peptidases exist to remove: aminopeptidases and endopeptidases reduce short peptides to free amino acids on a timescale of minutes after injection, and that enzymatic hydrolysis is the clearance mechanism, not renal or hepatic elimination of an intact drug. The free amino acid fraction is not cleared in any drug sense at all — it is consumed, entering the same pools as protein from a meal.

Here is what makes this page different from the other undefined mixture on this site: the assay is not impossible, and somebody has already built it. For the cousin preparation, a group developed a robust quantitative LC-MS/MS method for its main peptides, ran a pharmacokinetic study using a relative-exposure approach with mixed calibration curves, and concluded from the transient exposure of peptides in vivo that the product must work by a ‘hit and run’ pattern Zhang 2024. Read that as a demonstration of feasibility. A porcine brain hydrolysate can be given a measurable pharmacokinetic profile by choosing its most abundant peptides as surrogate analytes. Cerebrolysin has been marketed for decades and is described by the Cochrane review as widely used in Russia, Eastern Europe, China and other Asian countries Ziganshina 2023, and it has no equivalent published study. That absence is now a choice rather than a limitation.

And ‘hit and run’ is the right shape for the pharmacology, which is why it deserves stating rather than dismissing. If exposure is transient and the clinical effect is measured at 30 and 90 days Vester 2021, then whatever happens cannot be occupancy of a receptor for the duration. It has to be a brief trigger followed by a process that runs on its own — which is what the survival-pathway findings describe Wu 2021. It also means that steady-state thinking, and any dosing argument built on a 24-hour half-life, is the wrong model for this product.

Route, and the number that catches athletes. Every trial regimen above began with intravenous infusion Vester 2021. This site lists intramuscular. Beyond the volume arithmetic in the section above, the anti-doping rule that bites is about method rather than molecule: WADA prohibits intravenous infusions or injections exceeding 100 mL per 12-hour period outside legitimate hospital treatment. The trial's 50 mL/day sits under that ceiling — so the regimen with evidence would be permitted by volume, and the regimen people use has no evidence at all. Check the current Prohibited List rather than this paragraph.

What would have to be true, and how you would know it was not

Four predictions. The first translates an effect size that gets quoted constantly and explained never.

1. What a Mann-Whitney of 0.60 actually promises, and it is less than it sounds. The CAPTAIN result is MW = 0.60 Vester 2021. That statistic is the probability that a randomly chosen treated patient has a better outcome than a randomly chosen control. A coin is 0.50. So the promise is: 60 times in 100 instead of 50 times in 100. Real, statistically solid, and a long way from the language used to sell it. Prediction: any honest replication in moderate-to-severe traumatic brain injury reproduces something in the 0.55–0.65 range, not a transformation.

2. Against: MoCA will not move in a healthy adult over a 20-day course. Every positive result in this class comes from a brain with an acute lesion Vester 2021, and the mechanism as described is rescue of neurons that are dying Wu 2021. A healthy cortex has no such population. Draw the line at MoCA with alternate forms, baseline and 4 weeks. Prediction: flat, and the honest conclusion from flat is that the mechanism had no substrate rather than that the dose was too low.

3. Against, and this one comes from the safety data: adverse events should exceed placebo. The pooled non-fatal serious adverse event risk ratio is 2.39 with a confidence interval of 1.10 to 5.23 Ziganshina 2023. That interval excludes 1, which means it is a finding rather than a hint. Prediction: in any adequately sized cohort of healthy users, the adverse event rate on drug is higher than on placebo — and since no such cohort has ever been assembled, the individual version is to log every symptom daily rather than only the ones you were hoping for.

4. hs-CRP is the one blood marker with a mechanistic reason to move, and it should not move in you. The survival pathways credited to this class are anti-apoptotic and anti-inflammatory Wu 2021. In somebody with a genuinely elevated hs-CRP driven by an acute injury, a course could plausibly lower it. In a healthy person with a normal baseline there is nothing to lower. Draw hs-CRP before and at the end of a course, and do not draw it within two weeks of an infection or a hard training block, because both move it far harder than this will.

What nobody has tested yet

Five experiments. The first two would end an argument that has run for twenty years across two continents.

1. Nobody has published a peptide map of Cerebrolysin. The method exists and has been demonstrated on a porcine brain hydrolysate Zhang 2024. One LC-MS/MS run on five ampoules from different lots would produce, for the first time, a specification for a product that has been given to very large numbers of people. Its absence is why ‘same drug, different result’ can never be excluded when two trials disagree.

2. Nobody has run Cerebrolysin and cerebroprotein hydrolysate on the same column. One ampoule, one vial, one gradient, one afternoon. The result would either show two peptide distributions that overlap within lot-to-lot variation — in which case the two trial bases are evidence about one product and should be pooled — or it would show they are different preparations, in which case neither product's evidence may be quoted for the other. Every vendor page assumes one of those answers. Nobody has measured which.

3. No controlled trial has used the intramuscular route. Every regimen with evidence is intravenous first Vester 2021, and the volume arithmetic above says the trial dose cannot be given intramuscularly at all. So the route this product is actually used by on the gray market has never been tested at any dose, and cannot be tested at the dose that worked.

4. There is no dose-response study. CAPTAIN used 50 mL then 10 mL, in sequence, in every treated patient Vester 2021. No arm inside any trial compared two doses. Whether the effect sits on the rising limb of a curve, at its top, or past its peak is unknown for a drug in routine clinical use across several continents Ziganshina 2023.

5. Nobody has characterized the harm signal. A non-fatal serious adverse event risk ratio of 2.39 Ziganshina 2023 is a number with a mechanism-shaped hole behind it. What kinds of events? In which trials? Related to infusion volume, to the porcine origin, or to the underlying stroke? The review reports the ratio; nobody has gone back to the case reports and asked what happened to those people.

Cerebrolysin — its own safety story, not its class's

The class block is written for peptides and injectables generally. Four things here belong to this product alone, and the first is a number rather than a worry.

1. The harm signal is statistically significant, and almost nobody quotes it. Pooled across three trials and 1,335 participants, non-fatal serious adverse events ran at a risk ratio of 2.39, 95% CI 1.10 to 5.23, on moderate-certainty evidence, alongside no benefit on all-cause death Ziganshina 2023. The lower bound of that interval is above 1. This is the only compound in this cohort with a measured, significant excess of serious adverse events in a Cochrane review, and a page that omitted it in favor of the CAPTAIN result would be advertising.

2. It is porcine brain, injected, and that is a different risk from a synthetic molecule. Injecting material derived from another mammal's tissue can provoke anaphylactoid and anaphylactic reactions, and a preparation defined by a digestion endpoint rather than a formula cannot guarantee which peptide sequences came through. Sensitization makes a second course more dangerous than a first, not less. On the tissue itself, calibrate honestly: pigs are not known to carry a transmissible spongiform encephalopathy of the kind that made bovine brain material a public health problem, so the theoretical concern is smaller here than the phrase ‘brain-derived’ makes it feel. It is not zero, it is a reason to know the source species, and no vendor publishes sourcing controls.

3. The failure mode is substitution at an unreachable dose. Somebody running 5–10 mL intramuscularly over a course has bought a fraction of a regimen whose evidence comes from 50 mL a day intravenously in hospital Vester 2021, and has done so instead of the rehabilitation, sleep and training that carry the outcome. In moderate-to-severe traumatic brain injury under medical supervision the trials are real. In a healthy person at a gray-market dose by a different route, there is nothing — and the gap between those two sentences is where the money goes.

4. The identity question has a safety edge, not just a marketing one. If Cerebrolysin and cerebroprotein hydrolysate are the same class of preparation — and their own literature defines them identically Wu 2021 Zhang 2024 — then a person switching between them mid-course is switching manufacturers, specifications and units without knowing it, and this product's Cochrane harm signal is the more conservative one to carry across. Wide registration is a regulatory fact and not a safety finding; the safety finding is the confidence interval in point 1.

Sources read for this page

• Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2023;10:CD007026 · PMID 37818733
• Vester JC, Buzoianu AD, Florian SI, Homberg V, Kim SH, Lee TMC, Matula C, Poon WS, Sandesc D, von Steinbuchel N, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurological Sciences 2021;42(11):4531-4541 · PMID 33620612
• Zhang T, Liu Y, Wang G, Wang Z, Fan X, Shen Y, Liu W, Zhang D, He L, Xie L, Yu T, Liang Y. Evidence of the 'hit and run' characteristics of Cerebroprotein Hydrolysate-I in the treatment of neonatal HIE based on pharmacokinetic and pharmacological studies. International Immunopharmacology 2024;143(Pt 3):113580 · PMID 39547013
• Wu X, Liu Y, Zhu L, Wang Y, Ren Y, Cheng B, Ren L, Ge K, Li H. Cerebroprotein Hydrolysate-I Inhibits Hippocampal Neuronal Apoptosis by Activating PI3K/Akt Signaling Pathway in Vascular Dementia Mice. Neuropsychiatric Disease and Treatment 2021;17:2359-2368 · PMID 34305399
• Hua R, Hou Y, Yang L, Gao H, Yang F, Liu W, Jiang J, Wang B, Wu D. Efficacy and Safety of Cerebroprotein Hydrolysate I Combined with Rehabilitation Training in the Treatment of Provisional Intellectual Developmental Disorder in Children. Neuropsychiatric Disease and Treatment 2025;21:2067 · PMID 40964073

Cerebrolysin — safety, predicted from mechanism

Cerebrolysin — interference & stacking

Bloodwork to run alongside Cerebrolysin

Baseline first, then again at 8–12 weeks.

The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.

Check results you already have → · All 103 markers A–Z

Cerebrolysin — frequently asked questions

Cerebrolysin inside a finished plan

One arm of 2 Protocol Blueprints, free to read in full.

What Cerebrolysin is used for

Cerebrolysin appears under 2 goals in the goal router.

Related Cognitive & Mood compounds

← Explore the full Protocol Vault

↑ Back to on this page